VBLT News and Press, Vascular Biogenics Ltd. From 11/15/21

Conference Call and Webcast at 8:30 a.m. ET Today Data from multiple VB-111 clinical trials expected in 2022, including the progression free survival (PFS) co-primary endpoint from the Phase 3 OVAL study expected in the second half of 2022 More than 85% of the plan...

VBL Therapeutics (NASDAQ:VBLT) is scheduled to announce Q3 earnings results on Monday, November 15th, before market open. The consensus EPS Estimate is -$0.10 (+16.7% Y/Y) and the consensus Revenue Estimate is $0.13M (-31.6% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revis...

ACM, ACRX, ADN, AMPY, AVPT, AYRO, BCLI, BFLY, CLSN, OTCQB:CVSI, FREY, GMDA, GOED, KALA, MICT, OEG, ONDS, OTLY, PLX, PTN, RAIL, SOHU, TLS, TRVN, TSN, VBLT For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open

TEL AVIV, Israel and NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- VB L Therape u tics (Nasdaq: VBLT ), a clinical stage company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indi...

TEL AVIV, Israel and NEW YORK, Oct. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ) today announced the appointment of Sam Backenroth as chief financial officer (CFO) effective immediately. Mr. Backenroth is an accomplished corporate finance veteran with demonstrated s...

Corvus Pharmaceuticals (NASDAQ:CRVS) +56%. Innate Pharma (NASDAQ:IPHA) +32% Monalizumab data from COAST trial presented at ESMO Congress 2021 Surface Oncology (NASDAQ:SURF) +14%. BeiGene (NASDAQ:BGNE) +13% on positive DKN-01 + tislelizumab data in gastroesophageal cancer AbCell...

The OVAL Phase 3 clinical trial evaluating VB-111 in platinum-resistant ovarian cancer has recruited more than 320 patients (>80 %) to date; Remains on track to complete enrollment in 1Q22 TEL AVIV, Israel, Sept. 17, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NA...

TEL AVIV, Israel, Sept. 10, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics ( NASDAQ: VBLT ) today announced the Company will present in the following upcoming industry conferences: H.C. Wainwright 23rd Annual Global Investment Conference Mon., Sept. 13, 2021 Fireside chat...

Vascular Biogenics recently resumed dosing American patients in its OVAL Phase 3 trial. Trial enrollment should complete in 1H 2022. If the data is positive, the stock price should jump considerably. For further details see: Vascular Biogenics Trial Nears Full Enrollment...

Vinco Ventures (NASDAQ:BBIG) +65%. Aterian (NASDAQ:ATER) +52%. Support.com (NASDAQ:SPRT) +45%. Affirm Holdings (NASDAQ:AFRM) +40% as Amazon to integrate pay-over-time into its cart Globalstar (NYSE:GSAT) +36% on report iPhone 13 may use satellite connectivity Katapult...